Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

NCT03823131 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Treatment Ineffective

Conditions

Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Unresectable Head and Neck Squamous Cell Carcinoma

Interventions

DEVICE: ImmunoPulse
DRUG: Epacadostat
DRUG: Pembrolizumab
BIOLOGICAL: CORVax
DRUG: Tavokinogene telseplasmid

Sponsor

Chase Heaton, MD

Collaborators

[object Object]
[object Object]